Diagnostik der Zukunft: Wissen wir mit Proteomik und Genomik wirklich mehr?
|
|
- Vivian Welch
- 8 years ago
- Views:
Transcription
1 Diagnostik der Zukunft: Wissen wir mit Proteomik und Genomik wirklich mehr? Prof. Dr. J. Wiltfang Klinik für Psychiatrie und Psychotherapie (Direktor: Prof. Dr. J. Wiltfang), Rheinische Kliniken, Universität Duisburg-Essen
2 A. Alzheimer Amyloid cascade hypothesis of Alzheimer s Dementia extracellular soluble oligomers APP β secretase γ secretase Aβ peptides 1-40 & 1-42 amyloidogenic intermediates intracellular Tau & ptau neurodegeneration Aβ1-40 Aβ1-42 dementia MCI Amyloid fibrills neurofibrillary tangles neuoinflammation β amyloid plaques 2
3 BMB Liquor-Blut des KND Status: Liquor Blut, Baseline München LMU Erlangen Berlin Göttingen Bonn Freiburg Heidelberg Hamburg Düsseldorf Leipzig München TU International grösste, prospektive Liquor-Blut-DNA BMB für MCI & frühe Demenzen, Monitoring der Pränalytik, optimierte SOPs; Zum Vergleich: ADNI (USA): ca. 400 CSF Mannheim Homburg 3 3 Frankfurt 2 17 Gesamt
4 CSF-NDD: Predictive diagnostics of incipient AD? ApoE ε4 negative ApoE ε4 positive Total Tau (CSF, pg/ml) Aβ42/40 Ratio (CSF) Appr. 40% of the MCI patients show already the AD-indicative CSF profile and they are enriched in ApoE e4 (p<0.025) J. Wiltfang et al., Competence Net Dementias, unpublished data 4
5 CSF dementia biomarker and time to AD (Aβ1-42, total-tau, & phosho-tau181) 1.0 CSF normal: low risk for AD Probability of no AD CSF abnormal: high risk for AD Time (months) Hansson (2007) Lancet Neurology 5
6 The German CND Study (n=380) patients categorized according to the NDD data NDD status N CSF normal 153 CSF abnormal Test Mann-Whitney < p Aβ CSF abnormal CSF normal Groups analyzed Multiplexing of Aβ peptides in plasma (INNO-BIA assay) Median 25%-75% 10%-90% Wiltfang et al., oral presentation, AD conference, Washington 06/2007 6
7 Subset of the German CND Study (n=184) Group Disease group CSF criteria Clinical/Neuropsych. N MCI-AD-NDD+ MCI of AD type Aβ Ratio < 0.11 and ptau > 70 D-AD-NDD+ Early AD AβRatio < 0.11 and ptau > 70 MCI-O-NDD- D-O-NDD- MCI of non-ad type Early other dementia Aβ Ratio > 0.11 and ptau < 50 Aβ Ratio > 0.11 and ptau < 50 CDR = 0.5 and evidence of MCI-AD CDR > 0.5 and evidence of D-AD CDR = 0.5 and evidence of MCI-O CDR > 0.5 and evidence of D-O selection of patients according to clinical data supported by corresponding neurochemical dementia diagnostics (NDD) findings Wiltfang et al., oral presentation, AD conference, Washington 06/2007 7
8 Subset of the German CND Study Test Kruskal-Wallis p 0.12 Aβ Groups analyzed D-AD-NDD+ D-O-NDD- MCI-AD-NDD+ MCI-O-NDD- Median 25%-75% 10%-90% Wiltfang et al., oral presentation, AD conference, Washington 06/2007 8
9 Towards blood-based NDD?? Ray et al., Nature Medicine, 2007:published online
10 Blood-NDD: Accuracy for early and incipient AD claimed to be close to 90% Ray et al., Nature Medicine, 2007:published online
11 Summary: Neurochemical Dementia Diagnostics (CSF-NDD) CSF-NDD developed from former exclusion diagnostics to positive diagnostics of dementias Dementia biomarkers validated in independent multicenter studies: total-tau, phospho-tau, Aβ1-42 Diagnostic relevance for AD: phospho-tau > total-tau and ratio Aβ1-42/Aβ1-40 > Aβ1-42 A multiparametric diagnostic approach is superior to the use of single neurochemical dementia markers: diagnostic specificity & sensivitity for early AD 80-90%. CSF-NDD does enter international diagnostic guidelines Predictive CSF-based NDD of incipient AD To be validated: blood-based NDD Lewczuk et al., Wiltfang: Electrophoresis, 2004 Wiltfang et al.: Annals of Neurolgy, 2003 Wiltfang et al.:j. Neurochemistry, 2002 Wiltfang et al.: J. Biological Chemistriy, 2001 Itoh, Wiltfang et al.: Annals of Neurology, 2001 Otto et al., Wiltfang: Neurology, 2000 Bibl, et al., Wiltfang: Molecular Psychiatry, 2007 Bibl, et al., Wiltfang: Brain,
12 Vielen Dank für die Aufmerksamkeit 12
13 Single AβA peptides, AβA peptide ratio and total-tau Patients Alzheimer dementia (AD), n=22 non-ad dementia (nad), n=11 non-dementive mixed neuropsychiatric dieseases, i.e. disease controls (CON), n=35 CSF parameters and genotyping Aβx-42 & Aβx-40 (ELISA, The Genetics Company) ratio Aβx-42/AA 42/Aβx-4040 total-tau (ELISA, Innogenetics) ApoE-Genotypus (Innogenetics) Lewczuk P et al., Wiltfang J (2003) Neurobiology of Aging 13
14 CSF-NDD: Multiparameter Diagnostik Concentration of ttau in CSF (pg/ml ml) CON nad AD ApoE ε4+ AD ApoE ε Percentage ratio (Aβ42/40) of the Aβ peptide concentrations in CSF Lewczuk P et al., Wiltfang J (2003) Neurobiology of Aging 14
15 Comparative analysis of Receiver Operator Characteristic (ROC) for Aβx-42 and the ratio Aβx-42/AA 42/Aβx-4040 True Positive Sensitivity Aβ42 / 40 ratio Aβ Specificity False Positive The area under the curve (AUC) of the ratio (AUC=0.951) is superior to that of Aβx-42 A (AUC=0.926) Lewczuk P et al., Wiltfang J (2003) Neurobiology of Aging 15
16 Diagnostic relevance of the ratio Aβ42/40 for low- & high-aβ-load subjects CSF Aβ1-40 follows a normal distribution N=325 In low- or high-aβ-load subjects all Aβ peptide spezies 1-x are affected 60 N Aβx-40 in CSF (pg/ml) Wiltfang J et al. (2007) J Neurochem 16
17 Diagnostic relevance of the ratio Aβ42/40 for low- & high-aβ-load subjects Aß40 (pg/ml) Aß42 (pg/ml) Gesund AD Gesund AD Gesund AD Normal-Aβ-laod High-Aβ-laod Low-Aβ-laod Wiltfang J et al. (2007) J Neurochem 17
18 Diagnostic relevance of the ratio Aβ42/40 for low- & high-aβ-load subjects Aß42/Aß Gesund AD Gesund AD Gesund AD Normal-Aβ-laod High-Aβ-laod Low-Aβ-laod Wiltfang J et al. (2007) J Neurochem 18
19 Diagnostic relevance of the ratio Aβ42/40 for low- & high-aβ-load subjects CSF ptau181 (pg/ml) ) Low-Aβ-load, reduced Aβ1-42, but: normal Aβ ratio 2) High-Aβ-load, normal Aβ1-42, but: reduced Aβ ratio Median 25%-75% 10%-90% Wiltfang J et al. (2007) J Neurochem 19
20 The CSF Aβ ratio Aβ42/Aβ40 does predict incipient AD Baseline CSF analysis by urea-based Aβ-SDS-PAGE/immunoblot) of MCI (n=47) patients and contols (n=25); 4-6 years follow-up 0,24 0,22 0,20 0,18 p = p = (1) controls (n=25) (2) MCI MCI (n=25) (3) MCI AD (n=22) A 42/40 0,16 0,14 0,12 0,10 0,08 0,06 0, Mean Mean±SE Mean±SD In 19 out of 22 MCI patients (86%) incipient AD was predicted 4-6 years prior to the clinical manifestation of dementia by their baseline CSF Aβ ratio 42/40 Höglund et al., Blennow, Wiltfang: 2007, in press 20
21 Attomolar-sensitive Aβ-WIB A for blood Aβ peptides syn. Aβ syn. Aβ2-40 plasma CSF Also suprisingly stable Aβ peptide pattern in blood plasma! Lewczuk et al., Wiltfang: Electrophoresis,
22 Development of an attomolar sensitive SDS-PAGE/immunoblot for Aβ peptides Identification of the Aβ peptides by SELDI-TOF-MS, MALDI-TOF- MS, peptide synthesis & comigration 1,2 Aβ1-37 Aβ1-38 Aβ1-39 Aβ1-40 Aβ1-42 Aβ peptides Con AD 8M urea without urea The CSF Aβ peptide patterm is suprisingly stable 1 (correlation matrix of individual CSF Aβ peptides: r 1-n 0.90) Ct-truncated Aβ peptides are generated endoproteolytically 3 (studies in presenilin-1 deficient mice) 1 Wiltfang J et al., J. Neurochem., Lewczuk P, et al. Wiltfang J: Biol. Psychiatry, Wiltfang J et al., Journal of Biological Chemistry, 2001 EU Patent 22
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease Outline of Today s Lecture Why is Alzheimer s disease a problem? What is Alzheimer s Disease? What causes Alzheimer s disease? How can
More informationTotal Tau, p-taup ADNI subjects at BASELINE. Leslie M Shaw John Q Trojanowski
Total Tau, p-taup and 181p AβA 1- in 42 CSF of ADNI subjects at BASELINE Leslie M Shaw John Q Trojanowski ADNI Biomarker Core report, April 14, 28 Biomarker studies completed or planned ASELINE CSF samples:
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is an author's version which may differ from the publisher's version. For additional information about this
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this
More informationBiomarkers for Alzheimer's Disease in Down Syndrome
Biomarkers for Alzheimer's Disease in Down Syndrome Brad Christian, Ph.D. Waisman Laboratory for Brain Imaging Outline Rationale for Studying AD in Down Syndrome Background of Alzheimer s Disease Biomarkers
More informationPrimary Endpoints in Alzheimer s Dementia
Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in
More informationANXIETY, DEPRESSION AND NEURODEGENERATIVE DISEASES: NOVEL RESULTS IN THE DISCOVERY OF THEIR PATHOMECHANISMS AND NOVEL DRUG CANDIDATES
ANXIETY, DEPRESSION AND NEURODEGENERATIVE DISEASES: NOVEL RESULTS IN THE DISCOVERY OF THEIR PATHOMECHANISMS AND NOVEL DRUG CANDIDATES Botond Penke University of Szeged September 25, 2008. NEUROBIOLOGICAL
More informationClinical Applications of Imaging to Drug Development
Clinical Applications of Imaging to Drug Development Novartis Research: Disease Areas Massachusetts: Diabetes Infectious diseases Cardiovascular Oncology Great Britain: Chronic pain Respiratory New Jersey:
More informationBiobank Alliance. H.-Erich Wichmann. English version. Helmholtz Zentrum München LMU München
m 4 Biobank Alliance H.-Erich Wichmann English version Helmholtz Zentrum München LMU München Nationale Biobank Initiative Kickoff-Meeting 8. April 2011 TMF Berlin m 4 personalized medicine and target-orientated
More informationUniversity College Dublin Dublin, Ireland. Mabtech AB Nacka strand, Sweden
Faculty opponent Dominic M Walsh, Professor University College Dublin Dublin, Ireland Examining committee Niklas Ahlborg, Associate Professor Mabtech AB Nacka strand, Sweden Tommy Linné, Professor Swedish
More informationDeutsche Gesellschaft für Essstörungen German Association of Eating Disorders
Deutsche Gesellschaft für Essstörungen German Association of Eating Disorders President Prof. Dr. Martina de Zwaan University Erlangen Nürnberg Vice President Prof. Dr. Stephan Herpertz Ruhr Universität
More informationCEREBROSPINAL FLUID MARKERS FOR THE EARLY AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER S DISEASE
CEREBROSPINAL FLUID MARKERS FOR THE EARLY AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER S DISEASE Niki Schoonenboom SNM Schoonenboom, 2006, Amsterdam, the Netherlands. All rights reserved. ISBN-10: 90-9020990-5
More informationLocal Clinical Trials
Local Clinical Trials The Alzheimer s Association, Connecticut Chapter does not officially endorse any specific research study. The following information regarding clinical trials is provided as a service
More informationRESEARCHERS REPORT NEW WAYS TO PREDICT THE DEVELOPMENT OF ALZHEIMER S DISEASE
CONTACT: Alzheimer s Association AAIC newsroom, 202-249-4002, media@alz.org Niles Frantz, Alzheimer s Association, 312-363-8782, niles.frantz@alz.org RESEARCHERS REPORT NEW WAYS TO PREDICT THE DEVELOPMENT
More informationScandinavian Bio-Business Seminar, Zürich. Presentation 10 February 2016 Håkon Sæterøy, CEO
Scandinavian Bio-Business Seminar, Zürich Presentation 10 February 2016 Håkon Sæterøy, CEO Clinical need 75 m patients WW A global estimate of 75m patients with Mild Cognitive Impairment (MCI) who may
More informationEarly Changes in the Brain Proteome Associated with Alzheimer's Disease Risk
Early Changes in the Brain Proteome Associated with Alzheimer's Disease Risk Nicholas T. Seyfried Assistant Professor Departments of Biochemistry and Neurology Alzheimer s Disease Research Center Emory
More informationAutomatic Morphological Analysis of the Medial Temporal Lobe
Automatic Morphological Analysis of the Medial Temporal Lobe Neuroimaging analysis applied to the diagnosis and prognosis of the Alzheimer s disease. Andrea Chincarini, INFN Genova Clinical aspects of
More informationA Support System for Diagnosis of Dementia, Alzheimer or Mild Cognitive Impairment
Toronto, November 4, 2013 04:00 pm 05:30 pm-4th Oral Session A Support System for Diagnosis of Dementia, Alzheimer or Mild Cognitive Impairment Flávio L. Seixas Aura Conci Débora C. Muchaluat Saade Bianca
More informationCerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer s disease
original article J Bras Patol Med Lab, v. 51, n. 6, p. 376-382, December 2015 Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer s disease Aplicação de biomarcadores do fluido cerebrospinal
More informationCholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia
More informationAlzheimer s & Dementia 7 (2011) 280 292
Alzheimer s & Dementia 7 (2011) 280 292 Toward defining the preclinical stages of Alzheimer s disease: Recommendations from the National Institute on Aging-Alzheimer s Association workgroups on diagnostic
More informationBig Data Challenges: Data Management, Analytics & Security
Big Data Challenges: Data Management, Analytics & Security Ivo D. Dinov Statistics Online Computational Resource University of Michigan www.socr.umich.edu Big Data Challenges Availability, Sharing, Aggregation
More informationNormal and Abnormal Aging and the Brain. Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD
Normal and Abnormal Aging and the Brain Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD The myth of cognitive decline The myth of cognitive decline Individual change varies Individual change varies
More informationGERMAN UNIVERSITIES LIAISON OFFICES NEW YORK
GERMAN UNIVERSITIES LIAISON OFFICES NEW YORK German University Alliance (FU Berlin / LMU München) ConRuhr (Dortmund/ Duisburg-Essen / Bochum) Universität Heidelberg RWTH Aachen UAS 7 Hessen Universities
More informationIs there a Distinct Phenotype to Memory Loss in Alzheimer's Disease?
Is there a Distinct Phenotype to Memory Loss in Alzheimer's Disease? David A. Wolk, M.D. Assistant Director Penn Memory Center Assistant Professor of Neurology University of Pennsylvania 5 Million Clinical
More informationDiseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University
Diseases of the Nervous System Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University Outline A. Stress-related Disorders 1. Emotional Circuitry: Key Components 2. The Hypothalamic
More informationGOING BEYOND RISK REDUCTION: PHYSICAL EXERCISE MAY BE AN EFFECTIVE TREATMENT FOR ALZHEIMER S DISEASE AND VASCULAR DEMENTIA
CONTACT: Alzheimer s Association AAIC newsroom, 202-249-4002, media@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, niles.frantz@alz.org GOING BEYOND RISK REDUCTION: PHYSICAL EXERCISE MAY
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More information2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,
More informationNafith Abu Tarboush DDS, MSc, PhD natarboush@ju.edu.jo www.facebook.com/natarboush
Nafith Abu Tarboush DDS, MSc, PhD natarboush@ju.edu.jo www.facebook.com/natarboush α-keratins, bundles of α- helices Contain polypeptide chains organized approximately parallel along a single axis: Consist
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA PhD STUDIES SCHOOL. PhD THESIS - ABSTRACT -
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA PhD STUDIES SCHOOL PhD THESIS - ABSTRACT - SEARCHING THE MISSING LINK BETWEEN ALZHEIMER S DISEASE AND TYPE 2 DIABETES SCIENTIFIC COORDINATOR: Professor MARIA
More informationBiomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer s Disease
Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer s Disease Statistical Analysis Plan Introduction... Study Design and Objectives....
More informationBiomarker Discovery and Data Visualization Tool for Ovarian Cancer Screening
, pp.169-178 http://dx.doi.org/10.14257/ijbsbt.2014.6.2.17 Biomarker Discovery and Data Visualization Tool for Ovarian Cancer Screening Ki-Seok Cheong 2,3, Hye-Jeong Song 1,3, Chan-Young Park 1,3, Jong-Dae
More informationThe good things in life: can coffee consumption reduce the risk of developing Alzheimer s Disease?
can coffee consumption reduce the risk of developing Alzheimer s Disease? Contents 1. Foreword 2 2. The scale of the disease 3 3. Reducing the risk of developing Alzheimer s Disease 4 4. Epidemioligical
More informationMild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
Journal of Internal Medicine 2004; 256: 240 246 KEY SYMPOSIUM Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
More informationEiCon G.m.b.H. Diagnostic Healthcare Consulting. Amtsgericht Lörrach : HRB-Nr.3002. E-Mail : info@eiconnet.de. Home page: http://www.eiconnet.
EiCon G.m.b.H. Diagnostic Healthcare Consulting Amtsgericht Lörrach : HRB-Nr.3002 Unterbaselweg 55 D -79576 Weil am Rhein Germany Phone : (49) - 7621-798373 Fax : (49) - 7621-798374 Hauptstrasse 160 D-79576
More informationNeuropsychological Assessment of Early Cognitive Impairment in the Elderly
Neuropsychological Assessment of Early Cognitive Impairment in the Elderly David Loewenstein PhD, ABPP/CN Professor of Psychiatry and Behavioral Sciences Department of Psychiatry, Miller School of Medicine,
More informationNCRAD. Silver Alert System. Keeping Persons with AD Safe SILVER ALERT:
The National Cell Repository for Alzheimer s Disease (NCRAD) is a data and specimen collection source for families with Alzheimer disease (AD) or serious memory loss. Families having two or more living
More informationRetinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease
Retinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease Eleonora (Nora) Lad, MD, PhD Assistant Professor of Ophthalmology, Vitreoretinal diseases Duke Center for Macular Diseases Duke University
More informationPROMISING NEW TREATMENTS FOR ALZHEIMER S TARGET MULTIPLE DISEASE-RELATED PROTEINS, MAY HAVE BENEFITS FOR SEVERAL BRAIN DISEASES
CONTACT: Alzheimer s Association AAIC newsroom, 202-249-4002, media@alz.org Niles Frantz, Alzheimer s Association, 312-363-8782, niles.frantz@alz.org PROMISING NEW TREATMENTS FOR ALZHEIMER S TARGET MULTIPLE
More informationHow To Be A Psychologist
Dipl.-Psych. Christine Michel Contact Information Adresse Haupstraße 47-51 69117 Heidelberg Germany Telefon 0049 6221 547367 E-Mail Christine.Michel@psychologie.uni-heidelberg.de Education 10/2006 05/2012
More informationTeleconference Minutes November 17/18, 2011
Teleconference Minutes November 17/18, 2011 I. Attendance Maria Carrillo (Alzheimer s Association), Chris Rowe (AIBL), Arthur Toga, Mike Weiner (NA-ADNI), Cassandra Szoke (AIBL), Salvador Guinjoan (Arg-ADNI),
More informationPriv. Doz. Edna Grünblatt Ph.D., Medical Science, February 26, 2014
Curriculum Vitae Edna Grünblatt, Ph.D. Child and Adolescent Psychiatry Canton Zurich University of Zurich Head of the Neurobiochemistry Laboratory / Irchel Thurgauerstrasse 39 CH-8050 Zürich Tel: +41(0)44
More informationIntroduction to Proteomics
Introduction to Proteomics Åsa Wheelock, Ph.D. Division of Respiratory Medicine & Karolinska Biomics Center asa.wheelock@ki.se In: Systems Biology and the Omics Cascade, Karolinska Institutet, June 9-13,
More informationMaster of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science
CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The
More informationPolyphenols in the Prevention of Alzheimer s Disease:
Polyphenols in the Prevention of Alzheimer s Disease: some food for thought? By: Georgette-Marie Camilleri 4 th. year Medical Student University of Malta Contents What are polyphenols? Pathogenesis of
More informationThe Blood Donor BIOBANK
The Blood Donor BIOBANK the first successful combination of blood donation and biobanking for medical research 1 1 Zoglmeier et al., TRANSFUSION 2011, 51(5): 1121-1122 Dr. Franz Weinauer SWISSTRANSFUSION
More information8 th Senftenberg Innovation Forum on Multiparametric Analysis. May 7 8 2014 Senftenberg Germany
8 th Senftenberg Innovation Forum on Multiparametric Analysis AUTOIMMUNE Diagnostics May 7 8 2014 Senftenberg Germany In cooperation with: Media Partner: Recent developments of multiparametric technologies
More informationIKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics
Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex
More informationMonday, August 25, 2014
Danish Dementia Research Centre, Copenhagen University Kristian Steen Frederiksen, MD, PhD; Danish Dementia Research Centre, Copenhagen University Danish Dementia Research Centre, Copenhagen University
More information1. MSc Communication and Media Engineering (CME) University of Applied Sciences Offenburg
1. MSc Communication and Media Engineering (CME) University of Applied Sciences Offenburg 2. M.Sc. Computer Science with Media Applications Brandenburg University of Applied Sciences 3. M.Sc. Digital Media
More informationNew Hope: Stem Cell Therapy in Alzheimer's Disease
New Hope: Stem Cell Therapy in Alzheimer's Disease Mathew Blurton-Jones, Ph.D. Department of Neurobiology & Behavior Institute for Memory Impairments and Neurological Disorders Sue and Bill Gross Stem
More informationHow To Identify A Novel Pathway Leading To Myocardial Infarction
Press Release Embargo: 10 November 2013 at 1800 London time / 1300 US Eastern Time Genetic research identifies novel pathway leading to myocardial infarction Starting with a severely affected family, a
More informationNEALS Clinical Trials (Studies 1-5)
NEALS and NCRI Sample Repository Request Form Instructions & Descriptions The sample repository consists of serum, plasma, cerebrospinal fluid (CSF), urine, extracted DNA and whole blood samples from NEALS
More informationwww.iproteos.com Corporate Presentation November, 2013
www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)
More informationINTERNATIONAL RESEARCH GRANT PROGRAM ANNOUNCEMENT FISCAL YEAR 2016 JUNE 2016 PROGRAM (March 2016 August 2016)
INTERNATIONAL RESEARCH GRANT PROGRAM ANNOUNCEMENT FISCAL YEAR 2016 JUNE 2016 PROGRAM (March 2016 August 2016) I. BACKGROUND: ASSOCIATION MISSION AND SCIENTIFIC AGENDA...2 II. AREAS OF FOCUS FOR THE JUNE
More informationHarnessing the power of precision medicine to treat Alzheimer s and ALS February, 2016
Harnessing the power of precision medicine to treat Alzheimer s and ALS February, 2016 2 Forward looking statement: safe harbor This slide deck may contain certain forward-looking information. Such information
More informationTop 20 National Universities. Undergraduate Curricula and Graduate Expectations
PROFESSIONAL DEVELOPMENT WORKSHOP ON TEACHING NEUROSCIENCE Undergraduate Curricula and Graduate Expectations 9:00 Survey of undergraduate curricula Richard Olivo 9:20 Examples of psychology- and biology-based
More informationKernmodul Physiologie SS 2014
Kernmodul Physiologie 2014 The present module intends to provide a deeper understanding of physiology, ranging from molecular and cell physiology to integrative human physiology. You will be exposed to
More informationInstitut für Klinische Chemie und Laboratoriumsmedizin. In vitro Diagnostics in the Health Care System of Germany. Karl J. Lackner
In vitro Diagnostics in the Health Care System of Germany Karl J. Lackner Laboratory Medicine in Germany Major goal is to analyze body fluids (e.g. blood, urine, CSF) to support clinical diagnostics and
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationSurgery in Individuals Age 65+ Possible Risks. Possible Benefits. Potential Causes of POCD 11/24/2014. What is POCD?
Surgery in Individuals Age 65+ Postoperative Cognitive Dysfunction in Older Adults Ryan W. Schroeder, Psy.D., LP, ABPP-CN Neuropsychologist & Assistant Professor University of Kansas School of Medicine
More informationFrom metabiobanks to translational research platforms: Integrating Big Data through CRIP Tools
From metabiobanks to translational research platforms: Integrating Big Data through CRIP Tools 4 th Munich Biomarker Conference, November 26, 2014 christina.schroeder@izi-bb.fraunhofer.de Access to goods
More informationClinically Actionable Biomarkers in Rheumatoid Arthritis
Clinically Actionable Biomarkers in Rheumatoid Arthritis PepTalk January 6, 2009 William Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Health Care System T cell mediated Autoimmune
More informationTranslational research facilitating experimental medicine in dementia in the UK
Translational research facilitating experimental medicine in dementia in the UK Simon Lovestone Director Biomedical Research Unit for dementia at Maudsley and King s Route Map for Dementia Research June
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationThe shape of things to come: Young researchers in Germany
The shape of things to come: Young researchers in Germany Universitätsverband zur Qualifizierung des wissenschaftlichen Nachwuchses in Deutschland German University Association of Advanced Graduate Training
More informationADNI Data Training Part 2
ADNI Data Training Part 2 ADNI Biostatistics Core Team UC Davis School of Medicine Department of Public Health Sciences August 1, 2013 Outline Data Overview Today s Presentation Outline Data overview Commonly
More informationGeriatric Psychiatrists
Mentoring the Next Generation of Geriatric Psychiatrists Tips for Inspiring, Encouraging, and Guiding Medical Students 7910 Woodmont Avenue Suite 1050 Bethesda, MD 20814 phone: 3016547850 main@aagponline.org
More informationBiochemistry 1 Course Specifications. First year of M.B.B.Ch. Program
Faculty of Medicine Quality Assurance Unit Al-Azhar University Assuit Faculty of Medicine Biochemistry 1 Course Specifications First year of M.B.B.Ch. Program A- Professional information: Title: Biochemistry1
More informationPrevalence, incidence and risk factors of dementia in Cuban admixed population.
Prevalence, incidence and risk factors of dementia in Cuban admixed population. Authors: J. J. Llibre Rodriguez, J. C. Llibre Guerra, A. Valhuerdi, M. Guerra Hernandez, C. Ferri, M. Prince. Medical University.
More informationTotal tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
Acta Neurol Scand DOI: 10.1111/j.1600-0404.2010.01393.x Ó 2010 John Wiley & Sons A S ACTA NEUROLOGICA SCANDINAVICA Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive
More informationACTIVE-B12 EIA. the next level of B12 testing
ACTIVE-B12 EIA the next level of B12 testing Vitamin B12 an essential nutrient Vitamin B12 is an essential nutrient (can only be obtained from the diet) and is a vital component in many cellular functions
More informationLa Protéomique : Etat de l art et perspectives
La Protéomique : Etat de l art et perspectives Odile Schiltz Institut de Pharmacologie et de Biologie Structurale CNRS, Université de Toulouse, Odile.Schiltz@ipbs.fr Protéomique et Spectrométrie de Masse
More information2015 LEARNING GERMAN IN BONN. Sprache. Kultur. Deutschland.
2015 LEARNING GERMAN IN BONN Sprache. Kultur. Deutschland. INTENSIVE COURSES INTENSIVE COURSES INTENSIVE 4 Approx. four weeks, 17 days of lessons 85 UI (approx. 25 UI per week) max. class size: 16 1,070
More informationANTIBODIES AGAINST CITRULLINATED PEPTIDES IN EARLY RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE
ANTIBODIES AGAINST CITRULLINATED PEPTIDES IN EARLY RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE Principal investigators: Dr Raimon Sanmartí Sala Hospital Clínic i Provincial de Barcelona
More informationTreating patients with compounds or biological agents that pass the safety-test
Treating patients with compounds or biological agents that pass the safety-test There are numerous medical disorders without effective treatments. It is possible that many of un-treatable conditions need
More informationProject Narrative I.The Statement of Work: 1. First Year: 2. Second Year: 3. Third Year:
Project Summary/Abstract: Effects of traumatic brain injury and post traumatic stress disorder on Alzheimer s disease (AD) in Veterans using ADNI. Principal Investigator: Michael W. Weiner MD Key Words:
More informationI3 Interactions, Integrations and Innovations
Annual Meeting of the German Pharmaceutical Society DPhG I3 Interactions, Integrations and Innovations Düsseldorf, Germany September 23 25, 2015 at Heinrich Heine University Welcome Address Dear colleagues,
More informationUPDATE ON ALZHEIMER'S DISEASE CLINICAL TRIALS
UPDATE ON ALZHEIMER'S DISEASE CLINICAL TRIALS Laurie Ryan, PhD Program Director, Alzheimer s Disease Clinical Trials Dementias of Aging Branch Division of Neuroscience National Institute on Aging, National
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More information2014 Alzheimer s Disease Facts and Figures
2014 Alzheimer s Disease Facts and Figures Includes a Special Report on Women and Alzheimer s Disease Almost two-thirds of Americans with Alzheimer s disease are women. Alzheimer s Disease is the six eading
More informationThe Queen Sofía Foundation s Alzheimer s Disease Project
The Queen Sofía Foundation s Alzheimer s Disease Project Alzheimer s Disease Research Unit CIEN Foundation Queen Sofía Foundation Dr. P. Martínez Martín Scientific Director Alzheimer s Disease Research
More informationLibrary and Information Science Education in Germany
Library and Information Science Education in Germany Prof. Dr. Ursula Georgy Cologne University of Applied Sciences Institute of Information Science Goethe-Institute Lisboa, September 2005 Kind regards
More informationKnowledge Discovery and Data Mining
Knowledge Discovery and Data Mining Lecture 15 - ROC, AUC & Lift Tom Kelsey School of Computer Science University of St Andrews http://tom.home.cs.st-andrews.ac.uk twk@st-andrews.ac.uk Tom Kelsey ID5059-17-AUC
More informationBayesian Penalized Methods for High Dimensional Data
Bayesian Penalized Methods for High Dimensional Data Joseph G. Ibrahim Joint with Hongtu Zhu and Zakaria Khondker What is Covered? Motivation GLRR: Bayesian Generalized Low Rank Regression L2R2: Bayesian
More informationSince 1/2011 Supreme Administrative Court for Berlin-Brandenburg, JUDGE
Christoph Möllers Chair for Public Law and Legal Philosophy Faculty of Law Humboldt-Universität zu Berlin Unter den Linden 9 D-10099 Berlin Germany fon + 49 (0) 30 2093 3585 fax + 49 (0) 30 2093 3552 christoph.moellers@rewi.hu-berlin.de
More informationTrial Description. DRKS-ID: DRKS00006819 Date of Registration in DRKS: 2014/10/31 Date of Registration in Partner Registry: [---]* Title
Trial Description Title SCHILD - protective intervention for longtime course in depression Trial Acronym SCHILD URL of the trial [---]* Brief Summary in Lay Language Even if depression is treated appropriate
More informationSandro Sorbi DIPARTIMENTO DI SCIENZE NEUROLOGICHE E PSICHIATRICHE
Sandro Sorbi DIPARTIMENTO DI SCIENZE NEUROLOGICHE E PSICHIATRICHE L Ignoto, il Mistero, stimolano il pensiero, sono indispensabili al poeta ed all artista, aprono alla creatività. L Ignoto, il Mistero,
More informationANXIETY & COGNITIVE IMPAIRMENT
ANXIETY & COGNITIVE IMPAIRMENT Dr. Sherri Hayden, Ph.D., R. Psych. Neuropsychologist, UBC Hospital Clinic for Alzheimer Disease & Related Disorders Clinical Assistant Professor, UBC Department of Medicine,
More information1 in 3 seniors dies with Alzheimer s or another dementia.
2013 Alzheimer s disease facts and figures Includes a Special Report on long-distance caregivers 1 in 3 seniors dies with Alzheimer s or another dementia. Out-of-pocket expenses for long-distance caregivers
More informationBiomarkers in Clinical Neurosciences
Biomarkers in Clinical Neurosciences U. Bonuccelli,G.Siciliano, R.Ceravolo, M.Mancuso, L.Pasquali, G.Tognoni, F.Giorgi, F.Baldacci, D.Frosini, L.Kiferle,E.Bonanni (m.d.) A. Lo Gerfo, L. Chico, L.Petrozzi
More informationLinguistic Ability in Early Life and the Neuropathology of Alzheimer s Disease and Cerebrovascular Disease
Linguistic Ability in Early Life and the Neuropathology of Alzheimer s Disease and Cerebrovascular Disease Findings from the Nun Study D.A. SNOWDON, a,b L.H. GREINER, a AND W.R. MARKESBERY a,c a Sanders-Brown
More information2015 Alzheimer s Disease Facts and Figures
2015 Alzheimer s Disease Facts and Figures Includes a Special Report on Disclosing a Diagnosis of Alzheimer s Disease Alzheimer s Disease is the sixth-leading cause of death in the United States. more
More informationTHE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES. Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan. stern@umich.
THE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan stern@umich.edu ABSTRACT Risk stratification is most directly and informatively
More informationBMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.
March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding
More informationGerman International Student Barometer, D ISB, Academic Year 2011/12 Executive Summary
German International Student Barometer, D ISB, Academic Year 2011/12 Executive Summary Background The German International Student Barometer (D ISB) ran from 24 October to 9 December 2011, at 52 Hochschulen
More informationIdentification of Novel Biomarkers of Brain Injury by Integrating Bioinformatics and Mass Spectrometry-based Proteomics
Identification of Novel Biomarkers of Brain Injury by Integrating Bioinformatics and Mass Spectrometry-based Proteomics Collaborative Study 2 Introduction Brain injury: 1. Non-traumatic Infection Stroke
More informationGenomics Services @ GENterprise
Genomics Services @ GENterprise since 1998 Mainz University spin-off privately financed 6-10 employees since 2006 Genomics Services @ GENterprise Sequencing Service (Sanger/3730, 454) Genome Projects (Bacteria,
More informationA Cure for Alzheimer s Disease by 2025? The case against.
1 A Cure for Alzheimer s Disease by 2025? The case against. Dr. Howard Feldman Professor of Neurology Faculty of Medicine University of British Columbia Vancouver 2 Disclosure Consulting, lectures and
More information